Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive data dive: could old gout drugs shield against Alzheimer's?

NCT ID NCT04746989

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at health records from nearly 295,000 older adults with gout to see if two common gout medications, probenecid and allopurinol, affect the risk of developing dementia or Alzheimer's disease. The goal was to find out if one drug might be better at protecting the brain. Because this was a data analysis study, it did not involve new treatments or direct patient contact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

294,878 people

The number who actually took part.

Started

Feb 2021

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will involve a new user, parallel group, cohort study design comparing probenecid to allopurinol. The patients will be required to have continuous enrollment during the baseline period of 365 days before initiation of probenecid or allopurinol (cohort entry date). Follow-up for the outcome (incident dementia), begins the day after drug initiation for analyses 1, 3, and 4 and 180 days after drug initiation for analysis 2.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Please see https://docs.google.com/spreadsheets/d/1N3IVoirGdWS7OiKiOWWgPHhgsSxX7SWDIhpeeZ-Ft7c/edit?usp=sharing or Appendix A for full code and algorithm definitions. Medicare timeframe: 2007 to 2017 (end of data availability). Inclusion Criteria: * 1\. No prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date * 2\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date Exclusion Criteria: * 1\. Prior history of dementia measured anytime prior to cohort entry date * 2\. No prior history of gout recorded in the 365 days prior to cohort entry date * 3\. Prior history of nursing home admission in the 365 days prior to the cohort entry date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout Alzheimer disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.